SNP Genotyping and ApoE Genotyping
Huw Morris, Manuela MX Tan, Donald G Grosset, Nigel M Williams
Parkinson’s disease
Blood
DNA
Genotyping
Apolipoprotein E (APOE)
Single Nucleotide Polymorphisms (SNPs)
ASAPCRN
Abstract
This protocol details the steps for DNA extraction from a human blood sample, quality control, and SNP and APOE genotyping. The protocol has been adapted from the PRoBaND SNP Genotyping and ApoE Genotyping Protocol. The overall protocol for PRoBaND /Tracking Parkinson’s is published:
Malek, N., Swallow, D. M. A., Grosset, K. A., Lawton, M. A., Marrinan, S. L., Lehn, A. C., Bresner, C., Bajaj, N., Barker, R. A., Ben-Shlomo, Y., Burn, D. J., Foltynie, T., Hardy, J., Morris, H. R., Williams, N. M., Wood, N., & Grosset, D. G. (2015). Tracking Parkinson’s: Study Design and Baseline Patient Data. Journal of Parkinson’s Disease , 5 (4), 947–959. https://doi.org/10.3233/JPD-150662
Before start
Check the planned procedure is covered by existing Research Ethics Committee.
Check that you have the correct PPE, supplies and consumables.
Steps
Sample Collection and Genotyping
At study entry (baseline), collect a 4mL
blood sample in an ethylenediaminetetraacetic acid (EDTA) vacutainer for DNA extraction.
Perform DNA extraction.
Genotype DNA samples using the Illumina HumanCore Exome array with custom content following manufacturers instructions : https://www.illumina.com/products/by-type/microarray-kits/infinium-exome.html
Quality Control and Principle Component Analysis
Perform standard quality control procedures in PLINK v1.9:https://www.cog-genomics.org/plink//
Remove individuals:
With low overall genotyping rates (< 98%), related individuals (Identity-By-Descent PIHAT > 0.1) and heterozygosity outliers (> 2 SDs away from the mean)
Whose clinically reported biological sex did not match the genetically determined sex.
Conduct principle component analysis on a linkage disequilibrium (LD) pruned set of variants (removing SNPs with an r2 > 0.05 in a 50kb sliding window shifting 5 SNPs at a time) after merging with European samples from the HapMap reference panel.
Remove:
Individuals who are > 6 SDs away from the mean of any of the first 10 principal components.
Variants if they had a low genotyping rate (< 99%), Hardy-Weinberg Equilibrium p-value < 1 x 10-5, and minor allele frequency < 1%.
1,000 Genomes Project and APOE Genotyping
Following quality control, input genotypes separately to the 1,000 Genomes Project reference panel (phase 3 release 5) using the Michigan Imputation Server (https://imputationserver.sph.umich.edu).
Retain only variants with imputation quality >0.8, to keep only high quality calls to merge across the cohorts.
Tracking Parkinson’s data was lifted over to genome build hg38 using liftOver (https://genome.ucsc.edu/cgi-bin/hgLiftOver).
Recalculate the genetic principal components after removing outliers, as extreme outliers can substantially affect the calculation of genetic principal components.
These first 5 new principal components are included as covariates in future GWAS to adjust for population substructure
Additional outliers who are > 6 SDs away from the mean of any of the first 5 principal components are excluded.
Restrict genotyping of APOE to samples and SNPs that survive these QC procedures based on two common SNPs of the APOE gene: 388 T > C (rs429358) and 526C > T (rs7412).
The three haplotypes (ɛ2(388 T–526 T), ɛ3(388 T-526C), ɛ4(388C-526C)) and six genotypes (ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ3/ɛ3, ɛ3/ɛ4, ɛ4/ɛ4) formed by these SNPs are then used to determine ɛ4 status in each sample.